GlassScriptPhysician profile
Timothy Samuel Johnson
NPI 1023074119
$1,253.04
in general payments reported to CMS, 2019-2025
24 companies · $15.84 in 2025
The $15.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $227 · 2021: $12.45 · 2022: $12.20 · 2023: $163 · 2024: $180 · 2025: $15.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $345.91 | 2019-2024 | Farxiga, Breztri |
| Abbvie INC. | $126.66 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $102.10 | 2019-2020 | |
| Novo Nordisk INC | $87.96 | 2019-2020 | |
| Pfizer INC. | $65.83 | 2019-2020 | |
| Astellas Pharma US INC | $57.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.90 | 2019-2020 | |
| Lilly USA, LLC | $40.13 | 2019-2023 | Jardiance, Emgality |
| Allergan, INC. | $38.90 | 2019 | |
| Merck Sharp & Dohme LLC | $38.61 | 2019 | |
| Glaxosmithkline, LLC. | $36.79 | 2019-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $36.22 | 2023-2024 | Abilify Asimtufii, Rexulti |
| Circassia INC. | $34.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $34.22 | 2019-2020 | |
| Boston Scientific Corporation | $23.65 | 2023 | Wavewriter Alpha Prime 16 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.46 | 2019 | |
| Dexcom, INC. | $18.97 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $18.39 | 2019 | |
| Mylan Specialty L.P. | $16.67 | 2019 | |
| Shield Therapeutics INC | $15.26 | 2023 | Accrufer |
| Exact Sciences Corporation | $14.69 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $13.76 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $12.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.